ORDER A SIMILAR PAPER NOW

1. Management Plan: Write a final management plan for the client you presented with
bulimia. Include the following components in the management plan:
a. Primary diagnosis
b. Recommended diagnostic testing based on clinical practice guidelines
c. Medications
d. Nonpharmacologic interventions
e. Recommended follow-up schedule and referrals with rationale
2. Analysis: Complete an analysis of the case and management plan:
a. Pathophysiology: Write a summary of the underlying pathophysiology of the
diagnosis.
b. Pharmacology: Write a summary of how the pharmacological agent chosen
acts to reverse or control disease pathology.
c. Additional analysis: Describe how clinical practice guidelines were used to
make a diagnosis and management plan. If the case is based on a client you
have seen in practicum, discuss how the client’s care compared to the
recommended treatment guidelines.
d. Follow-up and referrals: Describe what actions should be taken at the time of
follow-up. If applicable, describe the client’s symptoms and response to the
plan of care at the follow-up visit.
e. Quality: Discuss any information you learned in the weekly discussion that
impacted your approach to the creation of the client’s management plan or
would inform your care of a future client with a similar disorder.
f. Coding and billing: Identify all appropriate ICD-10 codes for the client.
3. Evidence-Based Resources
a. Support the management plan and analysis with evidence from appropriate
sources published within the last five years and the most recent clinical
practice guidelines.
b. Select articles and guidelines that represent a logical link to the
management plan.
c. Provide in-text citations and complete APA references for all selected
scholarly resources

 

Struggling with where to start this assignment? Follow this guide to tackle your assignment easily!

---

1. Management Plan for Bulimia Nervosa

a. Primary Diagnosis:
Bulimia Nervosa (ICD-10: F50.2)
Characterized by recurrent episodes of binge eating followed by compensatory behaviors such as vomiting, excessive exercise, or laxative misuse.

---

b. Recommended Diagnostic Testing (per APA and NICE Guidelines):

• Complete Blood Count (CBC) – assess for anemia or infection

• Electrolytes, BUN, and Creatinine – evaluate for dehydration, electrolyte imbalance

• Serum amylase – may be elevated due to vomiting

• Electrocardiogram (ECG) – detect arrhythmias due to electrolyte imbalance

• Thyroid Function Tests – rule out metabolic causes

• Urinalysis – hydration status and renal function

---

c. Medications:

• Fluoxetine (Prozac): 60 mg/day (FDA-approved for bulimia nervosa)

  • Rationale: Shown to reduce binge-purge cycles and associated depressive symptoms.

---

d. Nonpharmacologic Interventions:

• Cognitive Behavioral Therapy (CBT) – first-line psychotherapy

• Nutritional counseling – normalize eating patterns

• Psychoeducation – teach about the effects of bulimia on health

• Family therapy – especially beneficial in adolescents

• Support groups – ongoing peer support

---

e. Recommended Follow-up and Referrals:

• Weekly follow-up during initial 12 weeks of treatment

• Psychiatry referral – for medication management and comorbid mood disorders

• Nutritionist referral – to develop structured meal plans

• Dental referral – to address enamel erosion or oral health concerns

• Rationale: Multidisciplinary care addresses the full spectrum of psychological, medical, and nutritional needs.

---

2. Analysis of Case and Management Plan

a. Pathophysiology:
Bulimia nervosa involves dysregulation of neurotransmitters, primarily serotonin and dopamine, which affect mood, impulse control, and appetite. Repeated binge-purge cycles lead to electrolyte imbalances, metabolic alkalosis, GI tract issues, and cardiac complications. Chronic vomiting can cause parotid gland swelling and esophageal irritation.

---

b. Pharmacology of Fluoxetine:
Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) that increases serotonin availability in the brain. This modulation helps control binge-eating urges and improves comorbid depressive symptoms, aiding in adherence to nonpharmacologic interventions.

---

c. Use of Clinical Practice Guidelines:
This management plan aligns with the APA Practice Guidelines (2023) and NICE Guidelines for bulimia nervosa, which recommend CBT and SSRIs, particularly fluoxetine, as first-line treatments. Clinical labs and ECGs are advised at baseline to identify medical risks prior to initiating treatment.

If this were based on a practicum case, the client’s initial management would be compared to the guidelines to assess gaps or strengths. If treatment aligned closely (e.g., combination therapy, medical monitoring), it would confirm guideline adherence.

---

d. Follow-up and Response to Care:
At follow-up, assess:

• Frequency of binge/purge episodes

• Side effects of medication

• Weight changes and lab monitoring

• Psychological symptoms
  In a typical case, a client might report reduced binge episodes by week 6 with improved mood and eating habits. Adjustments are made based on response and tolerability.

---

e. Quality Considerations:
Discussions during the week highlighted the importance of early screening for eating disorders and collaborative care models. This influenced the inclusion of a dietitian and mental health provider in the management plan to ensure holistic care.

---

f. ICD-10 Coding and Billing:

• F50.2 – Bulimia nervosa

• R63.2 – Polyphagia (if documented)

• R11.2 – Nausea with vomiting

• E87.6 – Hypokalemia (if present)

• Z71.3 – Dietary counseling and surveillance

---

3. Evidence-Based Resources

References (APA 7 format):

American Psychiatric Association. (2023). Practice guideline for the treatment of patients with eating disorders (4th ed.). https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines

National Institute for Health and Care Excellence. (2017). Eating disorders: Recognition and treatment (NG69). https://www.nice.org.uk/guidance/ng69

Mitchell, J. E., & Peterson, C. B. (2020). Eating disorders and comorbid conditions. Psychiatric Clinics of North America, 43(3), 381–394. https://doi.org/10.1016/j.psc.2020.05.004

Treasure, J., Stein, D., & Maguire, S. (2021). Treatment of eating disorders: A review of recent evidence. BMJ, 372, m4827. https://doi.org/10.1136/bmj.m4827

---

Let me know if you’d like this adapted into an MS Word format or need help with specific case data or references from your clinical practice.

ORDER A SIMILAR PAPER NOW